Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
21 mars 2024 09h00 HE
|
Sandoz Group
MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in EuropeAdditional manufacturing area of 3,000m2...
Sandoz receives FDA approval for first and only denosumab biosimilars
05 mars 2024 13h24 HE
|
Sandoz Group
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®*...
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
05 mars 2024 09h22 HE
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre genehmigten die 27. Dividendenerhöhung in Folge auf CHF 3,30 (+3,1 %) pro Aktie für 2023. Dies entspricht einer Rendite von 3,7%1 und einer Ausschüttung von rund 58%...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
05 mars 2024 09h22 HE
|
Novartis Pharma AG
Les actionnaires approuvent la 27e augmentation consécutive du dividende qui passe à CHF 3,30 (+3,1%) par action pour 2023 ; représentant un rendement de 3,7%1 et une distribution du free cash-flow...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
05 mars 2024 09h22 HE
|
Novartis Pharma AG
Shareholders approve 27th consecutive dividend increase to CHF 3.30 (+3.1%) per share for 2023; representing a 3.7% yield1 and approximately 58% payout of free cash flowShareholders confirm Joerg...
Sandoz announces nominations to the Board of Directors and leadership change
05 mars 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming...
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
04 mars 2024 01h15 HE
|
Novartis Pharma AG
The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies...
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
04 mars 2024 01h00 HE
|
Sandoz Group
MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team...
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
29 févr. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the classResolves...
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
05 févr. 2024 16h45 HE
|
Novartis Pharma AG
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or...